`Hearing on 10/04/2017
`
`ORIGINAL
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICAL INC.,
`Petitioner,
`v.
`MONOSOL RX, LLC,
`Patent Owner.
`
`Case IPR2017-00200
`Patent 8,603,514 B2
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`PAR PHARMACEUTICAL, INC. AND INTELGENX CORP.,
`Petitioners,
`v.
`MONOSOL RX, LLC,
`Patent Owner.
`
`Case IPR2017-01557
`Patent 8,603,514
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`DR. REDDY'S LABORATORIES S.A. and DR. REDDY'S
`LABORATORIES, INC.
`Petitioner,
`v.
`MONOSOL RX, LLC,
`Patent Owner.
`
`Case IPR2017-01582
`Patent 8,603,514
`
`PATENT TRIAL AND APPEAL BOARD HEARING
`
`Before Gina L. Smith, Certified Court Reporter
`
`Reported Telephonically
`
`On October 4, 2017, Commencing at 12:00 p.m.
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0001
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 2
`
`1
`
`MR. HAROLD FOX: Good afternoon, Your Honor. This
`
`2 is Harold Fox, lead counsel for Monosol in the three
`
`3 named IPR's. We do have a court reporter on the line.
`
`4 With me I have Dustin Weeks and Sharon Broma who are
`
`5 co-counsel, back-up counsel, on the 200 proceedings.
`
`6
`
`JUDGE FRANKLIN: And you are willing to
`
`7 participate in this combined call?
`
`8
`
`9
`
`MR. HAROLD FOX: Yes.
`
`JUDGE FRANKLIN: And also I'm going to ask that
`
`10 you file a copy of the transcript when it's available.
`
`11
`
`12
`
`13
`
`MR. HAROLD FOX: We will do so.
`
`JUDGE FRANKLIN: And, Petitioner Mylan.
`
`MR. STEVE PARMELEE: Good afternoon, Your Honor.
`
`14 This is Steve Parmelee, lead counsel for Petitioner
`
`15 Mylan Technologies, Inc. And we're here on the 2017-
`
`16 00200 and I guess the--I'm not sure if the other case
`
`17 is also involved in this call. My impression is it is
`
`18 not so we do not have a court reporter. We're willing
`
`19 to participate to the extent that this involves the
`
`20 termination discussion, termination of our proceeding,
`
`21 and that's the limited nature of our appearance this
`
`22 afternoon.
`
`23
`
`JUDGE FRANKLIN: And to clarify, the parties
`
`24 invited to this call are parties for your proceeding,
`
`25 IPR200 but also IPR2017-01557 and 01582. So having
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0002
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 3
`
`1
`
`2
`
`their participation in the call along with you and your
`
`case is what I'm seeking confirmation of whether you
`
`3
`
`agree or are willing to have this combined call.
`
`4
`
`5
`
`6
`
`MR. STEVE PARMELEE: Yes, Your Honor.
`
`JUDGE FRANKLIN: Thank you. And, Petitioner Par?
`
`MR. JONATHAN STRANG: Good morning, Your Honor.
`
`7 This is Jonathan Strang, counsel for Petitioner Par.
`
`8 And with me today I have Brenda Danek We do not have
`
`9 a court reporter. Patent Owner indicated it will file
`
`10 the transcript, and we do not object to the combined
`
`11 call.
`
`12
`
`JUDGE FRANKLIN: Thank you. And can you spell
`
`13 your last name for me.
`
`14
`
`MR. JONATHAN STRANG: Yes, Your Honor. S-T-R-A-N-
`
`15 G.
`
`16
`
`JUDGE FRANKLIN: Thank you. Petitioner Dr.
`
`17 Reddy's.
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`MR. IRA LEVY: Good afternoon, Your Honor. It is
`
`Ira Levy from Goodwin on behalf of Dr. Reddy's in
`
`IPR2017-01582. I am joined by my colleague Robert
`
`Frederickson, who has not appeared but will be
`
`appearing in the proceedings and we agree to join the
`
`joint call. And similar to Par, we understand that
`
`Patent Owner has a court reporter and will be filing
`
`25
`
`the transcript.
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0003
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 4
`
`1
`
`JUDGE FRANKLIN: Okay. Thank you all for that.
`
`2
`
`Before I talk to Par and Dr. Reddy's, the Petitioners
`
`3
`
`who urgently asked for this conference call, I'd like
`
`4
`
`to direct one question to Petitioner Mylan, Petitioner
`
`5
`
`of the 200IPR, a point of clarification.
`
`It seems that at least in one, perhaps in both,
`
`7
`
`with respect to the joinder in both 1557 and 1582 you
`
`8 may have indicated you do not oppose. We understand
`
`9 that Mylan and Monosol have reached a settlement in
`
`10 IPR200 and that as authorized have filed a motion to
`
`11 terminate that proceeding. In view of that settlement
`
`12 and that filing, does Mylan oppose the joinder request
`
`13 in 1557 and 1582?
`
`14
`
`MR. STEVE PARMELEE: Your Honor, we're here to
`
`15 talk about the termination of this 200 case. Our
`
`16 position has not changed on those joinders cases
`
`17 themselves.
`
`18
`
`JUDGE FRANKLIN: Okay. What I'm asking is for you
`
`19 to clarify then. You're telling us that you do not
`
`20 oppose joinder of 1557 and 1582 with you in the IRP200.
`
`21
`
`MR. STEVE PARMELEE: Well, we'd like to have this
`
`22 proceeding terminated. And what Your Honor does with
`
`23 the other cases and how they are treated doesn't
`
`24 necessarily turn on termination here.
`
`25
`
`JUDGE FRANKLIN: Correct. I just wanted to ask
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0004
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 5
`
`1 this one more time. This is for my clarification. I
`
`2 want to know your position. Apart from termination, do
`
`3 you have any issue with joinder with Par and Dr.
`
`4 Reddy's in the IPR200?
`
`5
`
`MR. STEVE PARMELEE: Our position is the same as
`
`6 we previously stated. We don't have an issue with the
`
`7 joinder petitioners or petitions, but we do want our
`
`8 proceeding terminated. We don't want responsibility for
`
`9 the IPR200 as it goes forward or if it is to go
`
`10 forward.
`
`11
`
`JUDGE FRANKLIN: Okay. And, Patent Owner, I think
`
`12 I understand from an email that you sent your position,
`
`13 but I want to give you an opportunity to respond to the
`
`14 same question.
`
`15
`
`MR. HAROLD FOX: Your Honor, this is Harold Fox.
`
`16 Dustin Weeks will be presenting for Patent Owner and
`
`17 can address that point.
`
`18
`
`MR. DUSTIN WEEKS: Yes, Your Honor, this is Dustin
`
`19 Weeks for Patent Owner. Patent Owner does oppose
`
`20 joinder of both--of Dr. Reddy's and Par in this case.
`
`21 And while we have not filed an opposition to the motion
`
`22 for joinder for Par, I guess depending on how this call
`
`23 goes today, Patent Owner would ask for authorization to
`
`24 submit additional briefing in both cases opposing
`
`25 joinder, given the change in circumstances due to the
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0005
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 6
`
`1
`
`2
`
`settlement with Mylan.
`
`JUDGE FRANKLIN: Okay. Thank you. Now let's turn
`
`3
`
`to Petitioners Par and Dr. Reddy's. Before I give an
`
`4
`
`opportunity to further explain your request I would
`
`5
`
`like to start with the question of, is your basis for
`
`6 wanting to oppose the motion to terminate an IPR200
`
`7 only as to its timing?
`
`8
`
`MR. JONATHAN STRANG: There's actually two aspects
`
`9 of that, Your Honor. Pardon me, this is Jonathan Strang
`
`10 for Petitioner Par and so the record--to make it clear
`
`11 for the record, we've coordinated with Dr. Reddy's and
`
`12 they're going to stay in the understudy role that they
`
`13 said they'd stay in in their motion for joinder. So,
`
`14 although they can speak up if they have any issues that
`
`15 affect only them.
`
`16
`
`And to answer your question, Your Honor, we oppose
`
`17 it only as to the Patent Owner. And as far as the
`
`18 timing goes, that is correct. Under Section 317 the
`
`19 Board has discretion to keep the IPR pending as to the
`
`20 Patent Owner and doesn't have that same discretion for
`
`21 the original petitioners. So Mylan is off the hook
`
`22 here. Our position is that the--we would like the Board
`
`23 to exercise its discretion that the Congress gave it to
`
`24 either hold the motion in abeyance or partially grant
`
`25 the motion to terminate, excusing Mylan from any
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0006
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 7
`
`1 further participation.
`
`2
`
`JUDGE FRANKLIN: And what is your basis for making
`
`3 that request?
`
`4
`
`MR. JONATHAN STRANG: Your Honor, well, the motion
`
`5 for joinder that we timely filed I think lays out the
`
`6
`
`reasons that joinder is appropriate here. It's the same
`
`7
`
`petition. We essentially copied in the same evidence,
`
`8
`
`the same expert. And as far as experts go, it isn't
`
`9
`
`clear from the public record so we don't know but if
`
`10
`
`we--a deposition after the Patent Owner's response has
`
`11 already occurred. If we're given a transcript of that
`
`12 we'll take that transcript and fold right into the
`
`13 schedule and file a reply in accordance with whatever
`
`14 schedule the Board grants so all the factors for
`
`15
`
`16
`
`17
`
`18
`
`19
`
`joinder are met. So what we're asking the Board here to
`
`do is actually exercise its discretion and hold the
`
`decision as to Patent Owner either in abeyance or to
`
`deny it. And we think the best reason for that is the
`
`public interest and having this meritorious challenge
`
`20
`
`to this patent continue.
`
`21
`
`JUDGE FRANKLIN: Okay. Thank you. And Mr. Levy,
`
`22
`
`did you want to add anything to Mr. Strang's comments?
`
`23
`
`24
`
`25
`
`MR. IRA LEVY: No, Your Honor. We join those
`
`comments that the Board does in fact have discretion
`
`and it has in fact exercised that discretion in other
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0007
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 8
`
`1 proceedings where it has, for example, continued IPR's
`
`2 on its own and then granted a petition for joinder. But
`
`3 continuing in that understudy role that we committed
`
`4 to, we agree and join with those arguments.
`
`5
`
`JUDGE FRANKLIN: And, Mr. Fox, would you like to
`
`6 respond?
`
`7
`
`MR. DUSTIN WEEKS: Your Honor, this is Dustin
`
`8
`
`Weeks for Patent Owner. I'll respond on behalf of
`
`9 Patent Owner, if that's okay.
`
`10
`
`11
`
`JUDGE FRANKLIN: Yes.
`
`MR. DUSTIN WEEKS: So Patent Owner doesn't believe
`
`12 the Board should hold any decision on this one motion
`
`13 to terminate in abeyance. Mylan and Monosol which are
`
`14 the parties in IPR200 have reached a settlement.
`
`15 They've resolved all issues between them. They've
`
`16 subsequently taken the appropriate action to terminate
`
`17 the proceeding, so Patent Owner would submit that the
`
`18 Board can now act on that motion in its entirety rather
`
`19 than prejudice either of these parties by holding the
`
`20 future of that case undecided.
`
`21
`
`We'll also note that both Par and Dr. Reddy's
`
`22 waited more than seven months after the Mylan petition
`
`23 before filing their own petition and because of their
`
`24 delay the Board's decision on the institution of those
`
`25 two cases isn't due until late December, and the
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0008
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 9
`
`1 current Mylan IPR for the due dates one and two have
`
`2 already passed, even though Mylan did not file a
`
`3 petition or reply on due date two. And by the time of
`
`4 the institution decision--or by the time the due date
`
`5 from the institution decisions in the Par and Dr.
`
`6 Reddy's IPR's each of due dates one through six and the
`
`7 Mylan IRP will have already passed and the oral hearing
`
`8
`
`will be just a few weeks later on January 10th. So if
`
`9 the Board decides--if it decides to wait on deciding
`
`10 the motion to terminate and then for some reason it
`
`11 ultimately joins Par and Dr. Reddy's, which Patent
`
`12 Owner opposes, then significant changes would need to
`
`13 be made to the scheduling order.
`
`14
`
`Patent Owner would also like to mention the Board
`
`15 shouldn't be forced to rush and consider the
`
`16 preliminary responses filed by Patent Owner to Dr.
`
`17 Reddy and the Par cases, but proposes preliminary
`
`18 responses presented in the arguments that weren't
`
`19 previously considered by the Board when instituting the
`
`20 Mylan IPR, the additional delay in resolving the Mylan
`
`21 IPR, which Par and Dr. Reddy's are now requesting will
`
`22 prejudice Patent Owner. And as I'm sure the Panel is
`
`23 aware, the Board has recently taken a strong stance
`
`24 against this harassment for follow-on petitions and
`
`25 repeated attacks against the same patent with this
`
`800-333-2082
`Huseby, Inc. Regional Centers
`vvww. huseb y. c o m
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0009
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 10
`
`1 General Plastics decision which was issued early
`
`2 September, and then the two subsequent decisions just
`
`3 last week in the Alere case and the Parrot case. For
`
`4 those reasons we would ask the Board to go ahead and
`
`5 decide the motion to terminate and not to delay this
`
`6 case any further.
`
`7
`
`JUDGE FRANKLIN: Okay. So I'd like to go through
`
`8 and allow the Petitioners in each party an additional
`
`9
`
`comment if they have one, beginning with counsel for
`
`10
`
`Mylan.
`
`11
`
`MR. STEVE PARMELEE: Thank you, Your Honor, I just
`
`12
`
`would say that we agree with Mr. Weeks' comments to the
`
`13
`
`14
`
`extent they address the termination of the Mylan
`
`Monosol IPR's specifically. And other than that we have
`
`15
`
`no further comments. Thank you.
`
`16
`
`17
`
`JUDGE FRANKLIN: And Mr. Strang.
`
`MR. JONATHAN STRANG: Yes, Your Honor, thank you.
`
`18 Just two followup. Some cases where the Board has seen
`
`19 similar situations is Microsoft v. Windy City in
`
`20 IPR2016-01155 and there the Board exercises discretion
`
`21 under 317, to only granting part. And likewise in ATT
`
`22 v. Convergent and that's IPR2017-01237, almost exactly
`
`23 the same facts as here. And, again, the Board went
`
`24 ahead and granted joinder.
`
`25
`
`I'm hearing Patent Owners' complaints about
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0010
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 11
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`scheduling but really the only delay in schedule here
`
`is going to be due to Patent Owner insisting on an
`
`opposition, and their time to oppose this motion for
`
`joinder passed long ago. And, in fact, they also
`
`opposed it in the Patent Owner preliminary response
`
`that was just filed.
`
`And in response to the points about General
`
`Plastics, well, that case just isn't really applicable
`
`here, Your Honor, because it's about serial petitions
`
`10
`
`and the unfairness in each petitioner picking up what
`
`11
`
`has been decided before and adding a little bit more
`
`12
`
`13
`
`14
`
`15
`
`and adding a little bit more until the Patent Owner has
`
`just been overwhelmed with all these different
`
`responses. In this case it's no difference for the
`
`Patent Owner regardless. The POR has already been
`
`16 filed. All we're going to do is file a petition of
`
`17 reply and go to oral argument, other than some motions
`
`18 practice.
`
`19
`
`And as far as the schedule goes, this case isn't
`
`20 exactly as Patent Owner noted in its argumentative
`
`21 email to the Board. All the facts are in front of the
`
`22 Board that are needed to decide this same petition as
`
`23 before. Patent Owner asked to file a sur-reply to the
`
`24 motion for joinder, which doesn't really make sense
`
`25 because a sur-reply would be our--which doesn't really
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0011
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 12
`
`1 make sense because they didn't oppose it. But, like
`
`2 said, they've already opposed it in the Patent Owner
`
`3 preliminary response. There's no need for any further
`
`4 briefing.
`
`5
`
`Subject to any questions, Your Honor, Petitioner
`
`6 Par doesn't have anything else.
`
`7
`
`JUDGE FRANKLIN: Thank you. And then I assume, Mr.
`
`8 Levy, you join in what Mr. Strang has said without
`
`9 further comment?
`
`10
`
`11
`
`MR. IRA LEVY: Yes, we do, Your Honor.
`
`JUDGE FRANKLIN: Okay. If the parties can please
`
`12 hold, I'm going to confer with my panel. I'll be back
`
`13 momentarily.
`
`14
`
`15
`
`[Off record 12:16 p.m. to 12:21 p.m.]
`
`JUDGE FRANKLIN: We were holding. I just want to
`
`16 confirm that we still have all the parties on the line.
`
`17 If you could just indicate yes when I call your name.
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Harold Fox and Mr. Weeks.
`
`MR. HAROLD FOX: Yes.
`
`MR. DUSTIN WEEKS: Yes, Your Honor.
`
`JUDGE FRANKLIN: Thank you. Mr. Parmelee.
`
`MR. STEVE PARMELEE: Yes, Your Honor.
`
`JUDGE FRANKLIN: Mr. Strang.
`
`MR. JONATHAN STRANG: Yes, Your Honor.
`
`JUDGE FRANKLIN: And Mr. Levy.
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0012
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 13
`
`MR. IRA LEVY: Yes, Your Honor.
`
`JUDGE FRANKLIN: Great. Thank you. I've conferred
`
`with the panel. We're going to take the matter under
`
`advisement. We will have an order for you shortly
`
`indicating how we'll resolve the issues raised today.
`
`If there's nothing further, we will adjourn. Thank you.
`
`[Hearing adjourns at 12:20 p.m.]
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8 //
`
`9 //
`
`10 //
`
`11 //
`
`12 //
`
`13 //
`
`14 //
`
`15 //
`
`16 //
`
`17 //
`
`18 //
`
`19 //
`
`20 //
`
`21 //
`
`22 //
`
`23 //
`
`24 //
`
`25 //
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC New York Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0013
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 14
`
`DISCLOSURE
`
`1
`
`2
`
`3 STATE OF GEORGIA
`
`4 COUNTY OF RICHMOND
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Pursuant to Article 10.B of the Rules and
`
`Regulations of the Board of Court Reporting of the
`
`Judicial Council of Georgia, I make the following
`
`disclosure:
`
`I am a Georgia Certified Court Reporter I am
`
`here as a representative of Prestige Reporting, LLC.
`
`Prestige Reporting was contacted to provide court
`
`reporting services for the deposition. Prestige
`
`Reporting will not be taking this deposition under any
`
`contract that is prohibited by O.C.G.A. Sec. 15-14-
`
`37(a) and (b).
`
`Prestige Reporting has no contract/agreement to
`
`provide reporting services with any party to the case,
`
`any counsel in the case, or any reporter or reporting
`
`agency from whom a referral might have been made to
`
`cover this deposition. Prestige Reporting will charge
`
`its usual and customary rates to all parties in the
`
`case, and a financial discount will not be given to any
`
`party to this litigation.
`
`Dated: 10/04/17; GINA L. SMITH, CCR, CVR-M, B-2151
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0014
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 15
`
`1
`
`CERTIFICATE
`
`2 STATE OF GEORGIA:
`
`3 COUNTY OF RICHMOND:
`
`I hereby certify that the foregoing transcript was
`
`taken down, as stated in the caption, and the colloquy,
`
`questions, and answers thereto were reduced to
`
`typewriting under my direction; that the foregoing
`
`pages 2 through 13 represent a true, complete, and
`
`correct transcript of the evidence given.
`
`I further certify that I am not related to or are
`
`of counsel to the parties in the case; am not in the
`
`regular employ of counsel for any of said parties; nor
`
`am I in any way interested in the result of said case.
`
`This, the 6th day of October, 2017.
`
`• of
`
`GINA L. SMITH, CCR, CVR-M, B-2151
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19 //
`
`20 //
`
`21 /7
`
`22 //
`
`23 /7
`
`24 //
`
`25 //
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0015
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: 00200-City
`
`0
`
`act
`
`8 : 18
`
`action
`
`8 : 16
`
`argument
`11 : 17
`
`00200
`
`2 : 16
`
`add 7 : 22
`
`01582
`
`2 : 25
`
`1
`
`10th 9 : 8
`
`12:16 12 : 14
`
`12:20 13 : 7
`
`12:21 12 : 14
`
`1557 4:7,
`13,20
`
`1582 4:7,
`13,20
`
`2
`
`200 2:5
`4:15
`
`200IPR 4 : 5
`
`2017- 2 : 15
`
`3
`
`317 6:18
`10:21
`
`A
`
`abeyance
`6:24 7:17
`8:13
`
`accordance
`7 : 13
`
`adding
`11 : 11,12
`
`additional
`5:24 9:20
`10 : 8
`
`address 5 : 17
`10 : 13
`
`adjourn 13 : 6
`
`adjourns
`13 : 7
`
`advisement
`13 : 4
`
`affect
`
`6:15
`
`afternoon
`2:1,13,22
`3:18
`
`agree 3:3,22
`8:4 10:12
`
`ahead 10:4,
`24
`
`Alere 10 : 3
`
`appearance
`2 : 21
`
`appeared
`3 : 21
`
`appearing
`3 : 22
`
`applicable
`11 : 8
`
`argumentative
`11:20
`
`23 10:4,
`18,20,23
`11:21,22
`
`Board's 8:24
`
`arguments
`8:4 9:18
`
`both- -of
`5 : 20
`
`aspects
`
`6 : 8
`
`Brenda 3 : 8
`
`assume 12:7
`
`ATT 10:21
`
`attacks
`
`9:25
`
`authorization
`5:23
`
`authorized
`4 : 10
`
`aware 9 : 23
`
`B
`
`back 12 : 12
`
`back-up 2 : 5
`
`basis
`7:2
`
`6 : 5
`
`beginning
`10 : 9
`
`behalf 3:19
`8:8
`
`bit 11:11,
`12
`
`Board 6:19,
`22 7:14,
`15,24
`8:12,18
`9:9,14,19,
`
`briefing
`5 : 24 12 : 4
`
`Broma 2 : 4
`
`C
`
`call
`2:7,
`17,24 3:1,
`3,11,23
`4:3 5:22
`12:17
`
`case 2:16
`3:2 4:15
`5:20 8:20
`10:3,6
`11:8,14,19
`
`cases 4:16,
`23 5:24
`8:25 9:17
`10:18
`
`challenge
`7 : 19
`
`change 5 : 25
`
`changed 4 : 16
`
`circumstances
`5 : 25
`
`City 10 : 19
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte - Atlanta - Washington, DC - New York - Houston - San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0016
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: clarification-experts
`
`clarification
`4:5 5:1
`
`considered
`9:19
`
`decided
`11:11
`
`clarify
`4:19
`
`2:23
`
`clear 6:10
`7:9
`
`co-counsel
`2:5
`
`colleague
`3:20
`
`continue
`7:20
`
`continued
`8:1
`
`continuing
`8:3
`
`Convergent
`10:22
`
`combined 2:7
`3:3, 1 0
`
`coordinated
`6:11
`
`1
`
`: 9
`
`copied 7:7
`
`copy 2:10
`
`correct
`6:18
`
`4:25
`
`counsel 2:2,
`5,14 3:7
`10:9
`
`comment
`12:9
`
`comments
`7:22,24
`10:12,15
`
`committed
`8 : 3
`
`complaints
`10:25
`
`decides 9:9
`
`decides --if
`9:9
`
`deciding 9:9
`
`decision
`7:17 8:12,
`24 10:1
`
`decision --or
`9:4
`
`decisions
`9:5 10:2
`
`delay 8:24
`9:20 10:5
`11:1
`
`deny 7 : 18
`
`depending
`5:22
`
`court 2:3,18
`3:9,24
`
`deposition
`7:10
`
`confer 12:12
`
`current
`
`9:1
`
`didn' t 12:1
`
`6:20 8:11
`11:24,25
`12:6
`
`don' t 5:6, a
`7 : 9
`
`due 5:25
`8:25 9:1,
`3,4,6 11:2
`
`Dustin 2 : 4
`5:16,18
`8:7,11
`12:20
`
`E
`
`early 10:1
`
`email 5:12
`11:21
`
`entirety
`8:18
`
`essentially
`7:7
`
`evidence 7:7
`
`excusing
`6:25
`
`exercise
`6:23 7:16
`
`exercised
`7 : 25
`
`exercises
`10:20
`
`expert
`
`7 : 8
`
`conference
`4:3
`
`conferred
`13:2
`
`confirm
`12:16
`
`D
`
`Danek 3 : 8
`
`date
`
`9 : 3,4
`
`dates
`
`9 : 1, 6
`
`confirmation
`3:2
`
`December
`8:25
`
`Congress
`6:23
`
`decide 10:5
`11:22
`
`difference
`11:14
`
`direct
`
`4 : 4
`
`discretion
`6:19,20,23
`7:16,24,25
`10:20
`
`discussion
`2:20
`
`doesn't
`
`4 : 23
`
`experts
`
`7 : 8
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte - Atlanta - Washington, DC - New York - Houston - San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0017
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: explain..Ira
`
`explain
`
`6 : 4
`
`extent
`10 : 13
`
`2 : 19
`
`F
`
`fact 7 : 24 ,
`25 11 : 4
`
`factors
`
`7 : 14
`
`facts 10 : 23
`11 : 21
`
`2:10
`file
`3:9 7:13
`9:2 11:16,
`23
`
`4 : 10
`filed
`5:21 7:5
`9 : 16 11 : 6 ,
`16
`
`3 : 24
`filing
`4:12 8:23
`
`fold
`
`7 : 12
`
`follow-on
`9 : 24
`
`followup
`10 : 18
`
`forced 9 : 15
`
`forward 5:9,
`10
`
`Fox 2:1,2,
`8,11 5:15
`8:5 12:18,
`19
`
`FRANKLIN
`2:6,9,12,
`23 3:5,12,
`16 4:1,18,
`25 5:11
`6:2 7:2,21
`8:5,10
`10:7,16
`12:7,11,
`15,21,23,
`25 13:2
`
`Frederickson
`3 : 21
`
`front 11 : 21
`
`future
`
`8 : 20
`
`G
`
`gave 6:23
`
`General 10 : 1
`11 : 7
`
`give 5 : 13
`6:3
`
`Good 2:1,13
`3:6,18
`
`Goodwin 3 : 19
`
`grant
`
`6 : 24
`
`granted 8:2
`10 : 24
`
`granting
`10 : 21
`
`grants
`
`7 : 14
`
`Great 13 : 2
`
`guess 2 : 16
`5 : 22
`
`insisting
`11:2
`
`H
`
`harassment
`9 : 24
`
`Harold 2:1,
`2,8,11
`5:15
`12:18,19
`
`hearing 9 : 7
`10:25 13:7
`
`hold 6:24
`7:16 8:12
`12:12
`
`holding 8 : 19
`12 : 15
`
`Honor 2:1,13
`3:4,6,14,
`18 4:14,22
`5:15, 18
`6:9,16
`7:4,23 8:7
`10:11,17
`11:9 12:5,
`10,20,22,
`24 13:1
`
`hook 6 : 21
`
`I
`
`impression
`2 : 17
`
`indicating
`13 : 5
`
`instituting
`9:19
`
`institution
`8:24 9 : 4,5
`
`interest
`7:19
`
`invited
`
`2 : 24
`
`involved
`2 : 17
`
`involves
`2 : 19
`
`IPR 6:19
`9:1,20,21
`
`IPR200 2:25
`4:10 5:4,9
`6:6 8:14
`
`IPR2016-01155
`10:20
`
`IPR2017-01237
`10:22
`
`IFR2017-01557
`2:25
`
`IPR2017-01582
`3:20
`
`2 : 3
`IPR' S
`8:1 9:6
`10:14
`
`Ira 3:18,19
`7:23 12:10
`13:1
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte - Atlanta - Washington, DC - New York - Houston - San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0018
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: IRP-opposition
`
`IRP
`
`9
`
`: 7
`
`11:4,24
`
`limited 2 : 21
`
`long 11 : 4
`
`M
`
`made 9 : 13
`
`make
`6 : 10
`11 : 24 12 : 1 .
`
`Mylan 2:12,
`15 4:4,9,
`12 6:1,21,
`25 8:13,22
`9:1,2,7,20
`10:10,13
`
`N
`
`making 7 : 2
`
`named 2 : 3
`
`matter 13 : 3
`
`nature
`
`2 : 21
`
`mention 9 : 14 necessarily
`4 : 24
`
`needed 11 : 22
`
`note 8 : 21
`
`noted 11 : 20
`
`0
`
`object
`
`3 : 10
`
`occurred
`7 : 11
`
`opportunity
`5:13 6:4
`
`oppose 4:8,
`12,20 5:19
`6:6,16
`11:3 12:1
`
`opposed 11 : 5
`12 : 2
`
`opposes 9:12
`
`opposing
`5:24
`
`opposition
`
`IRP200
`
`4:20
`
`j oinders
`4:16
`
`7:8
`isn't
`8:25 11:8, joined 3 : 20
`19
`
`joins
`
`9 : 11
`
`joint
`
`3 : 23
`
`Jonathan
`3:6,7,14
`6:8,9 7:4
`10:17
`12:24
`
`issue
`
`5 : 3,6
`
`issued 10 : 1
`
`issues 6:14
`8:15 13:5
`
`2:10
`it's
`7:6 11:9,
`14
`
`I'd 4:3
`10:7
`
`8:8
`I'll
`12:12
`
`I'm 2:9 3:2
`4:18 9:22
`10:25
`12:12
`
`I've 13:2
`
`JUDGE 2:6,9, meritorious
`7 : 19
`12,23 3:5,
`12,16 4:1,
`18,25 5:11
`6:2 7:2,21
`8:5,10
`10:7,16
`12:7,11,
`15,21,23,
`25 13:2
`
`met 7 : 15
`
`Microsoft
`10:19
`
`momentarily
`12 : 13
`
`Monosol 2:2
`4:9 8:13
`10:14
`
`L
`
`months 8 : 22
`
`J
`
`late 8:25
`
`morning 3 : 6
`
`January 9:8
`
`lays 7:5
`
`join 3:22
`7:23 8:4
`12:8
`
`joinder 4:7,
`12,20 5:3,
`7,20,22,25
`6:13 7:5,
`6,15 8:2
`10:24
`
`lead
`
`2:2,14
`
`let's
`
`6:2
`
`Levy 3:18,
`19 7:21,23
`12:8,10,25
`13:1
`
`likewise
`10 : 21
`
`motion 4:10
`5:21 6:6,
`13,24,25
`7:4 8:12,
`18 9:10
`10:5 11:3,
`24
`
`motions
`11 : 17
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0019
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: oral..raised
`
`5:21 11:3
`
`oral 9:7
`11:17
`
`order 9:13
`13:4
`
`original
`6 : 21
`
`our- -which
`11 : 25
`
`overwhelmed
`11 : 13
`
`Owner 3:9,24
`5:11,16,
`19,23
`6:17,20
`7:17 8:8,
`9,11,17
`9:12,14,
`16,22
`11:2,5,12,
`15,20,23
`12:2
`
`Owners 10 : 25
`
`Owner' s 7 : 10
`
`P
`
`p.m. 12:14
`13:7
`
`panel 9:22
`12:12 13:3
`
`Par 3:5,7,
`23 4:2
`5:3,20,22
`6:3,10
`
`8:21 9:5,
`11,17,21
`12:6
`
`11:2,5,12,
`15,20,23
`12 : 2
`
`Pardon 6 : 9
`
`pending 6:19
`
`Parmelee
`2:13,14
`3:4 4:14,
`21 5:5
`10:11
`12:21,22
`
`Parrot 10 : 3
`
`part 10 : 21
`
`partially
`6:24
`
`participate
`2:7,19
`
`participation
`3 : 1 7 : 1
`
`parties
`2:23,24
`8:14,19
`12:11,16
`
`party 10:8
`
`petition 7:7
`8:2,22,23
`9:3 11:16,
`22
`
`petitioner
`2:12,14
`3:5,7,16
`4:4 6:10
`11:10 12:5
`
`petitioners
`4:2 5:7
`6:3,21
`10:8
`
`petitions
`5 : 7 9 : 24
`11:9
`
`picking
`11 : 10
`
`Plastics
`10 : 1 11 : 8
`
`passed 9:2,7
`11:4
`
`point 4:5
`5:17
`
`patent 3:9,
`24 5:11,
`16,19,23
`6:17,20
`7:10,17,20
`8:8,9,11,
`17 9:11,
`14,16,22,
`25 10:25
`
`points 11 : 7
`
`POR 11:15
`
`position
`4:16 5:2,
`5,12 6:22
`
`practice
`11 : 18
`
`prejudice
`8 : 19 9 : 22
`
`preliminary
`9:16,17
`11:5 12:3
`
`presented
`9 : 18
`
`presenting
`5 : 16
`
`previously
`5 : 6 9 : 19
`
`proceeding
`2:20,24
`4:11,22
`5:8 8:17
`
`proceedings
`2 : 5 3 : 22
`8 : 1
`
`proposes
`9 : 17
`
`public 7 : 9 ,
`19
`
`Q
`
`question 4 : 4
`5 : 14 6 : 5 ,
`16
`
`questions
`12 : 5
`
`R
`
`raised 13 : 5
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte - Atlanta - Washington, DC - New York - Houston - San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0020
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: reached..the--Pm
`
`reached 4 : 9
`8:14
`
`resolving
`9 : 20
`
`reason 7 : 18
`9 : 10
`
`reasons 7 : 6
`10 : 4
`
`recently
`9 : 23
`
`record 6:11
`7 : 9 12 : 14
`
`record- - to
`6:10
`
`Reddy 9 : 17
`
`Reddy' s
`3:17,19
`4:2 5:4,20
`6:3,11
`8:21 9:6,
`11,21
`
`repeated
`9 : 25
`
`reply 7 : 13
`9:3 11 : 17
`
`reporter
`2 : 3,18
`3 : 9,24
`
`4 : 12
`request
`6:4 7 : 3
`
`requesting
`9:21
`
`resolve 13 : 5
`
`resolved
`8:15
`
`respect
`
`4 : 7
`
`respond 5:13
`8 : 6,8
`
`response
`7:10 11:5,
`7 12 : 3
`
`responses
`9 : 16,18
`11 : 14
`
`responsibility
`5:8
`
`Robert 3 : 20
`
`6 : 12
`
`role
`8:3
`
`rush 9 : 15
`
`S
`
`S - t -r- a-n-
`3 : 14
`
`schedule
`7 : 13,14
`11 : 1,19
`
`scheduling
`9 : 13 11 : 1
`
`Section
`
`6 : 18
`
`seeking 3:2
`
`sense 11 : 24
`12 : 1
`
`September
`10:2
`
`serial
`
`11 : 9
`
`23,24
`
`settlement
`4:9,11 6:1
`8:14
`
`Sharon 2 : 4
`
`shortly 13 : 4
`
`shouldn' t
`9 : 15
`
`significant
`9 : 12
`
`similar
`10 : 19
`
`3 : 23
`
`situations
`10 : 19
`
`speak 6 : 14
`
`specifically
`10 : 14
`
`spell
`
`3 : 12
`
`Strang' s
`7:22
`
`strong
`
`9 : 23
`
`Subject 12 : 5
`
`submit 5 : 24
`8:17
`
`subsequent
`10:2
`
`subsequently
`8 : 16
`
`sur- reply
`11:23,25
`
`T
`
`talk
`
`4 : 2,15
`
`Technologies
`2 : 15
`
`stance
`
`9 : 23
`
`telling
`
`4:19
`
`start
`
`6 : 5
`
`stated
`
`5 : 6
`
`6 : 12 ,
`
`stay
`13
`
`Steve 2:13,
`14 3:4
`4:14,21
`5:5 10:11
`12:22
`
`Strang 3 : 6,
`7,14 6:8,9
`7:4 10:16,
`17 12 : 8 ,
`
`terminate
`4:11 6:6,
`25 8:13,16
`9:10 10:5
`
`terminated
`4:22 5 : 8
`
`termination
`2:20 4:15,
`24 5 : 2
`10:13
`
`2 :21
`that' s
`8:9 10:22
`
`the--i'm
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte - Atlanta - Washington, DC - New York - Houston - San Francisco
`
`Dr. Reddys v. MonoSol
`IPR2017-01582
`
`MonoSol2005-0021
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: the--we-You're
`
`2 : 16
`
`the --we 6 : 22
`
`6 : 8
`there' s
`12 : 3 13 : 6
`
`they' d 6 : 13
`
`unfairness
`11 : 10
`
`Y
`
`urgently
`
`4 : 3
`
`You're 4 : 19
`
`V
`
`they're
`
`6 : 12
`
`view 4 : 11
`
`they've
`12 : 2
`
`8 : 15
`
`time 5 : 1
`9 : 3,4 11 : 3
`
`timely 7 : 5
`
`timing 6 : 7 ,
`18
`
`today 3 : 8
`5 : 23 13 : 5
`
`transcript
`2:10 3:10,
`25 7:11,12
`
`treated
`
`4 : 23
`
`4 : 24
`
`turn
`6 : 2
`
`U
`
`ultimately
`9 : 11
`
`undecided
`8 : 20
`
`understand
`3 : 23 4 : 8
`5 : 12
`
`understudy
`6 : 12 8 : 3
`
`W
`
`wait 9 : 9
`
`waited 8 : 22
`
`wanted 4 : 25
`
`wanting 6 : 6
`
`we--a
`
`7 : 10
`
`week 10 : 3
`
`weeks 2 : 4
`5:16,18,19
`8 : 7,8,11
`9 : 8 10 : 12
`12:18,20
`
`weren' t
`
`9 : 18
`
`we'd 4:21
`
`7 : 12
`we'll
`8:21 13:5
`
`we're 2:15,
`18 4 : 14
`7 : 11,15
`11 : 16 13 : 3
`
`we've
`
`6 : 11
`
`Windy 10